- Home
- LDWY vs SBFM Comparison
LDWY vs SBFM Comparison
Compare LDWY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- SBFM
- Stock Information
- Founded
- LDWY 1990
- SBFM 2006
- Country
- LDWY United States
- SBFM United States
- Employees
- LDWY N/A
- SBFM N/A
- Industry
- LDWY Advertising
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- SBFM Health Care
- Exchange
- LDWY Nasdaq
- SBFM Nasdaq
- Market Cap
- LDWY 9.2M
- SBFM 7.7M
- IPO Year
- LDWY 1991
- SBFM N/A
- Fundamental
- Price
- LDWY $4.94
- SBFM $1.44
- Analyst Decision
- LDWY
- SBFM Strong Buy
- Analyst Count
- LDWY 0
- SBFM 1
- Target Price
- LDWY N/A
- SBFM $15.00
- AVG Volume (30 Days)
- LDWY 6.8K
- SBFM 77.5K
- Earning Date
- LDWY 08-18-2025
- SBFM 08-15-2025
- Dividend Yield
- LDWY N/A
- SBFM N/A
- EPS Growth
- LDWY N/A
- SBFM N/A
- EPS
- LDWY N/A
- SBFM N/A
- Revenue
- LDWY $42,183,000.00
- SBFM $36,234,578.00
- Revenue This Year
- LDWY N/A
- SBFM $192.48
- Revenue Next Year
- LDWY N/A
- SBFM N/A
- P/E Ratio
- LDWY N/A
- SBFM N/A
- Revenue Growth
- LDWY 425.12
- SBFM 35.51
- 52 Week Low
- LDWY $3.02
- SBFM $1.17
- 52 Week High
- LDWY $5.53
- SBFM $8.78
- Technical
- Relative Strength Index (RSI)
- LDWY 55.84
- SBFM 45.66
- Support Level
- LDWY $4.85
- SBFM $1.39
- Resistance Level
- LDWY $5.12
- SBFM $1.54
- Average True Range (ATR)
- LDWY 0.13
- SBFM 0.11
- MACD
- LDWY -0.04
- SBFM -0.01
- Stochastic Oscillator
- LDWY 58.33
- SBFM 9.46
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.